Feasibility of SPECT-CT Imaging to Study the Pharmacokinetics of Antisense Oligonucleotides in a Mouse Model of Duchenne Muscular Dystrophy-Reference-Cited by-同舟云学术

Feasibility of SPECT-CT Imaging to Study the Pharmacokinetics of Antisense Oligonucleotides in a Mouse Model of Duchenne Muscular Dystrophy

Published:2017-08 Issue:4 Volume:27 Page:221-231
ISSN:2159-3337
Container-title:Nucleic Acid Therapeutics
language:en
Short-container-title:Nucleic Acid Therapeutics

Author:

van de Steeg Evita¹,Läppchen Tilman²,Aguilera Begoña³,Jansen Harm T.¹,Muilwijk Daan³,Vermue Rick³,van der Hoorn José W.¹,Donato Katia²,Rossin Raffaella²,de Visser Peter C.³,Vlaming Maria L.H.¹

Affiliation:

1. TNO, Zeist, the Netherlands.

2. Department Minimally Invasive Healthcare, Philips Research, Eindhoven, the Netherlands.

3. BioMarin Nederland BV, Leiden, the Netherlands.

Publisher

Mary Ann Liebert Inc

Subject

Drug Discovery,Genetics,Molecular Biology,Molecular Medicine,Biochemistry

Link

http://www.liebertpub.com/doi/pdf/10.1089/nat.2016.0649

Reference21 articles.

1. Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases

2. Antisense Oligonucleotides: Treating Neurodegeneration at the Level of RNA

3. Dystrophin: The protein product of the duchenne muscular dystrophy locus

4. Increasing complexity of the dystrophin-associated protein complex.

5. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biodistribution of Radioactively Labeled Splice Modulating Antisense Oligonucleotides After Intracerebroventricular and Intrathecal Injection in Mice;Nucleic Acid Therapeutics;2024-02-01

2. The Pharmacokinetics of 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides: Experiences from Developing Exon Skipping Therapies for Duchenne Muscular Dystrophy;Nucleic Acid Therapeutics;2019-12-01

3. The macrophage as a Trojan horse for antisense oligonucleotide delivery;Expert Opinion on Therapeutic Targets;2018-06-03